While our study highlights the therapeutic potential of PRMT1 inhibition combined with CBP in multiple preclinical models, including PDX, we acknowledge inherent limitations of PDX models.[17] Despite their ability to better replicate human tumor heterogeneity compared to cell lines, PDX models exhibit inter‐sample variability due to factors such as the tumor microenvironment, patient‐specific characteristics, and engraftment in immunodeficient mice, which may affect treatment response consistency. This evidence concerns the gene PRMT1 and neoplasm.